Press Releases for SGEN

Press Releases
Seattle Genetics Announces Exercise of Over-Allotment Option
Seattle Genetics Announces Pricing of Public Offering of Common Stock
Seattle Genetics Announces Proposed Public Offering of Common Stock
Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration with MedImmune
StockPreacher.com Issues Trading Outlook for Onyx Pharmaceuticals Inc. (ONXX)
Seattle Genetics Initiates Brentuximab Vedotin (SGN-35) Retreatment Clinical Trial
Seattle Genetics Reports Strong Pipeline Progress and Second Quarter 2009 Financial Results
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2009 Financial Results on July 23, 2009
Seattle Genetics Initiates Phase II Trial of SGN-35 for Anaplastic Large Cell Lymphoma
Seattle Genetics Reports Data from SGN-35 Every Three Week Dosing Phase I Trial in Lymphoma
Seattle Genetics Presents Final Lintuzumab Phase I Clinical Data
Seattle Genetics to Present at the Needham Life Sciences Conference
Seattle Genetics Reports Data from a Weekly Dosing Phase I Clinical Trial of SGN-35 in Lymphoma
Seattle Genetics to Present SGN-35 and Lintuzumab Clinical Data at the European Hematology Association Congress
Seattle Genetics Announces SGN-35 Clinical Data to be Presented at the American Society of Clinical Oncology Annual Meeting
Seattle Genetics to Present at Upcoming Investor Conferences
Seattle Genetics Reports Product Development Progress and First Quarter 2009 Financial Results
Seattle Genetics Presents Preclinical Data on Antibody-Drug Conjugate Programs at AACR
Seattle Genetics Highlights Dacetuzumab Preclinical Research at AACR
Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2009 Financial Results on April 23, 2009
Seattle Genetics Announces Management Team Addition and Promotion to Support SGN-35 Commercialization Initiatives
Seattle Genetics Announces Antibody-Drug Conjugate Collaboration With Millennium
Seattle Genetics Receives FDA Fast Track Designation for SGN-35 for the Treatment of Hodgkin Lymphoma
Seattle Genetics to Present at the Needham Cancer Therapeutics Conference
Seattle Genetics to Present at Upcoming Investor Conferences - Mar 4 2009 9:24AM
Seattle Genetics Completes Enrollment in Lintuzumab Phase IIb Clinical Trial for Patients with Acute Myeloid Leukemia
Seattle Genetics Initiates Pivotal Trial of SGN-35 for Hodgkin Lymphoma
Seattle Genetics Reports Fourth Quarter and Year 2008 Financial Results and Provides 2009 Financial Outlook
Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2008 Financial Results on February 5, 2009
Seattle Genetics Announces Pricing of Common Stock Offering
Seattle Genetics Receives Orphan Drug Designations for SGN-35 in the United States and Europe
Seattle Genetics Receives Special Protocol Assessment for SGN-35 Pivotal Trial in Hodgkin Lymphoma
Seattle Genetics to Present at the J.P. Morgan Healthcare Conference
Seattle Genetics Announces Interim Safety Analysis Supports Continuation of Lintuzumab Phase IIb Clinical Trial
Seattle Genetics Reports Durable Objective Responses with SGN-35 in Lymphoma
Seattle Genetics Reports Objective Responses with Dacetuzumab in Phase II Non-Hodgkin Lymphoma Trial
Seattle Genetics to Present at Upcoming Investor Conferences - Dec 1 2008 9:29AM
Seattle Genetics to Present at the Oppenheimer Healthcare Conference
Seattle Genetics Presents Preclinical Data on Antibody-Drug Conjugate Programs
Seattle Genetics Reports Development Progress and Third Quarter 2008 Financial Results
Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2008 Financial Results on October 23, 2008
Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration with Progenics
Seattle Genetics Adds to Senior Management Team
Seattle Genetics to Present at the UBS Global Life Sciences Conference
Seattle Genetics to Present at Upcoming Investor Conferences - Aug 27 2008 9:18AM
Seattle Genetics Initiates SGN-70 Phase I Clinical Trial
Seattle Genetics Reports Second Quarter 2008 Financial Results
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2008 Financial Results on July 22, 2008
Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration Triggered by Genentech's IND Filing
Seattle Genetics Announces SGN-35 Plenary Presentation at International Conference on Malignant Lymphoma
Seattle Genetics Reports Final SGN-40 Phase I Non-Hodgkin Lymphoma Data at International Conference on Malignant Lymphoma
Seattle Genetics to Present at Upcoming Investor Conferences - Jun 4 2008 9:10AM
Seattle Genetics Reports Multiple Complete and Partial Responses with SGN-35 in Patients with Lymphoma
Seattle Genetics Announces Initiation of SGN-40 Phase Ib Clinical Trial in Combination With Velcade for Multiple Myeloma
CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
Seattle Genetics Announces Upcoming SGN-35 Presentation at the American Society of Clinical Oncology Annual Meeting - May 27 2008 12:55AM
Seattle Genetics to Present at Upcoming Investor Conferences - Jun 2 2008 3:53AM
Seattle Genetics Reports First Quarter 2008 Financial Results
Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2008 Financial Results on April 24, 2008
Seattle Genetics Presents Preclinical Data on its Antibody-Drug Conjugate Technology and SGN-33 Program at AACR
Seattle Genetics Highlights SGN-70 at AAI Annual Meeting
Seattle Genetics Announces Initiation of Phase Ib Clinical Trial of SGN-40 in Combination with Rituxan and Gemzar for Non-Hodgkin Lymphoma
MedImmune Licensing New Antibody-Enhancing Technologies to Further Strengthen its Development-Stage Pipeline
Protein Design Labs Sublicenses Rights to Develop Antibody-Drug Conjugates for Prostate Cancer to Genentech, Inc.